tiprankstipranks
Press Releases

Novartis AG, AstraZeneca Plc, and Pfizer Inc Among Leading Companies in the Thyroid Cancer Pipeline Products Market | Globaldata Plc

LONDON, July 05, 2022 (GLOBE NEWSWIRE) — The “Thyroid Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report offered by GlobalData Plc provides comprehensive information on the therapeutics under development for thyroid cancer (oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. It also reviews key players involved in therapeutic development for thyroid cancer and features dormant and discontinued projects.

Leading Companies in the Thyroid Cancer Pipeline Products Market

  • Novartis AG: It is a healthcare company that provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others.
  • Advenchen Laboratories LLC: It is a pharmaceutical company that conducts research and develops small molecule cancer drug discovery programs. It provides pipeline such as angiogenesis inhibitors and small molecule protein tyrosine kinases inhibitors, among others.
  • Loxo Oncology Inc: It is a biopharmaceutical company that carries out the development of targeted small molecule therapeutics for the treatment of cancer.
  • AstraZeneca Plc: It is a biopharmaceutical company, which develops products related to therapy areas such as respiratory, cardiovascular, renal, and metabolic diseases, cancer, autoimmune, infection, and neurological diseases.
  • Pfizer Inc: It offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders, and rare diseases.

Some Other Companies Covered in the Thyroid Cancer Pipeline Products Market Report

  • F. Hoffmann-La Roche Ltd
  • CSPC Pharmaceutical Group Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Merck & Co Inc
  • AffyImmune Therapeutics Inc

Thyroid Cancer Pipeline Products Market Analysis, by Leading Companies

To know about more leading thyroid cancer pipeline product companies, download a sample report

Key Thyroid Cancer Pipeline Products Market Segment Highlights

The thyroid cancer pipeline products market report is segmented by target, MoA, RoA, and molecule type.

Thyroid Cancer Pipeline Products Market Segment Analysis by Target

  • Proto Oncogene Tyrosine Protein Kinase Receptor Ret
  • Vascular Endothelial Growth Factor Receptor 2
  • Serine/Threonine Protein Kinase B Raf
  • Programmed Cell Death Protein 1
  • Epidermal Growth Factor Receptor
  • Vascular Endothelial Growth Factor Receptor 3
  • Others

Number of Thyroid Cancer Pipeline Products, by Target

Download a sample report for detailed target insights on the thyroid cancer pipeline products market

Thyroid Cancer Pipeline Products Market Segment Analysis by MoA

  • Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor
  • Vascular Endothelial Growth Factor Receptor 2 Inhibitor
  • Serine/Threonine Protein Kinase B Raf Inhibitor
  • Programmed Cell Death Protein 1 Antagonist
  • Vascular Endothelial Growth Factor Receptor 3 Inhibitor
  • Mast/Stem Cell Growth Factor Receptor Kit Inhibitor
  • Epidermal Growth Factor Receptor Inhibitor
  • Others

Number of Thyroid Cancer Pipeline Products, by MoA

Download a sample report for detailed MoA insights on the thyroid cancer pipeline products market

Thyroid Cancer Pipeline Products Market Segment Analysis by RoA

  • Oral
  • Intravenous
  • Subcutaneous
  • Intratumor
  • Intravenous Drip
  • Parenteral
  • Others

Number of Thyroid Cancer Pipeline Products, by RoA

Download a sample report for detailed RoA insights on the thyroid cancer pipeline products market

Thyroid Cancer Pipeline Products Market Segment Analysis by Molecule Type

  • Small Molecule
  • Monoclonal Antibody
  • Cell Therapy
  • Synthetic Peptide
  • Gene-Modified Cell Therapy
  • Monoclonal Antibody Conjugated
  • Recombinant Protein
  • Others

Number of Thyroid cancer Pipeline Products, by Molecule Type

Download a sample report for detailed molecule type insights on the thyroid cancer pipeline products market

Thyroid Cancer Pipeline Products Market Report Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of thyroid cancer (oncology).
  • The pipeline guide reviews pipeline therapeutics for thyroid cancer (oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in thyroid cancer (oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates thyroid cancer (oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for thyroid cancer (oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for thyroid cancer (oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding thyroid cancer (oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

Related Reports

  • Aicardi-Goutieres Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Click here
  • Neuroendocrine Tumors Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Click here
  • Alport Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape – Click here
  • Cancer Anorexia-Cachexia Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update – Click here
  • Hypopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update – Click here

Thyroid Cancer Pipeline Products Market Overview

Targets Proto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor 2, Serine/Threonine Protein Kinase B Raf, Programmed Cell Death Protein 1, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor 3, and Others
Mechanisms of Action Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Serine/Threonine Protein Kinase B Raf Inhibitor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Epidermal Growth Factor Receptor Inhibitor, and Others
Routes of Administration Oral, Subcutaneous, Intravenous, Intratumor, Intravenous Drip, Parenteral, and Others
Molecule Types Small Molecule, Monoclonal Antibody, Cell Therapy, Recombinant Protein,
Synthetic Peptide, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, and Others
Leading Companies Novartis AG, Advenchen Laboratories LLC, Loxo Oncology Inc, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, CSPC Pharmaceutical Group Ltd, Jiangsu Hengrui Medicine Co Ltd, Merck & Co Inc, AffyImmune Therapeutics Inc, and Others

FAQs

What are the key targets in the thyroid cancer pipeline products market?
The key targets in the thyroid cancer pipeline products market are Proto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor 2, Serine/Threonine Protein Kinase B Raf, Programmed Cell Death Protein 1, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor 3, and others.

What are the key mechanisms of action in the thyroid cancer pipeline products market?
Some of the mechanisms of action of the thyroid cancer pipeline products market are Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Serine/Threonine Protein Kinase B Raf Inhibitor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Epidermal Growth Factor Receptor Inhibitor, and others.

What are the routes of administration in the thyroid cancer pipeline products market?
The routes of administration in the thyroid cancer pipeline products market are oral, subcutaneous, intravenous, intratumor, intravenous drip, parenteral, and others.

What are the molecule types in the thyroid cancer pipeline products market?
The molecule types in the thyroid cancer pipeline products market are small molecule, monoclonal antibody, cell therapy, recombinant protein, synthetic peptide, gene-modified cell therapy, monoclonal antibody conjugated, and others.

Which are the leading companies in the thyroid cancer pipeline products market?
Some of the key companies in the thyroid cancer pipeline products market are Novartis AG, Advenchen Laboratories LLC, Loxo Oncology Inc, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, CSPC Pharmaceutical Group Ltd, Jiangsu Hengrui Medicine Co Ltd, Merck & Co Inc, AffyImmune Therapeutics Inc, and others.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Thyroid Cancer – Overview

Thyroid Cancer – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Thyroid Cancer – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Thyroid Cancer – Companies Involved in Therapeutics Development

Thyroid Cancer – Drug Profiles

Thyroid Cancer – Dormant Projects

Thyroid Cancer – Discontinued Products

Thyroid Cancer – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

About us

GlobalData is a leading provider of data, analytics, and insights on the world’s largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision makers to predict and navigate the future. This is why GlobalData’s mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.

Media Contacts

GlobalData

Mark Jephcott
Head of PR EMEA
mark.jephcott@globaldata.com
cc: pr@globaldata.com

+44 (0)207 936 6400

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More